Polio antiviral drugs (PAVDs) may provide a critical tool in the eradication endgame by stopping poliovirus infections in immunodeficient individuals who may not clear the virus without therapeutic intervention. Although prolonged/chronic poliovirus excreters are rare, they represent a source of poliovirus reintroduction into the general population. Prior studies that assumed the successful cessation of all oral poliovirus vaccine (OPV) use estimated the potential upper bound of the incremental net benefits (INBs) of resource investments in research and development of PAVDs. However, delays in polio eradication, OPV cessation, and the development of PAVDs necessitate an updated economic analysis to reevaluate the costs and benefits of further investments in PAVDs.
Methods
Using a global integrated model of polio transmission, immunity, vaccine dynamics, risks, and economics, we explore the risks of reintroduction of polio transmission due to immunodeficiency-related vaccine-derived poliovirus (iVDPV) excreters and reevaluate the upper bound of the INBs of PAVDs.
Results
Under the current conditions, for which the use of OPV will likely continue for the foreseeable future, even with successful eradication of type 1 wild poliovirus by the end of 2023 and continued use of Sabin OPV for outbreak response, we estimate an upper bound INB of 60 million US$2019. With >100 million US$2019 already invested in PAVD development and with the introduction of novel OPVs that are less likely to revert to neurovirulence, our analysis suggests the expected INBs of PAVDs would not offset their costs.
Conclusions
While PAVDs could play an important role in the polio endgame, their expected economic benefits drop with ongoing OPV use and poliovirus transmissions. However, stakeholders may pursue the development of PAVDs as a desired product regardless of their economic benefits.
Highlights
While polio antiviral drugs could play an important role in the polio endgame, their expected economic benefits continue to drop with delays in polio eradication and the continued use of oral poliovirus vaccines.
The incremental net benefits of investments in polio antiviral drug development and screening for immunodeficiency-related circulating polioviruses are small.
Limited global resources are better spent on increasing global population immunity to polioviruses to stop and prevent poliovirus transmission.
TangyeSGAl-HerzWBousfihaAA, et al. Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2020;40:24–64. DOI: 10.1007/s10875-019-00737-x
2.
BousfihaAAJeddaneLPicardC, et al. Human inborn errors of immunity: 2019 update of the IUIS phenotypical classification. J Clin Immunol. 2020;40:66–81. DOI: 10.1007/s10875-020-00758-x
3.
Duintjer TebbensRJPallanschMAKewOM, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal. 2006;26:1471–505. DOI: 10.1111/j.1539-6924.2006.00827.x
MacCallumPO. Observations on the feeding of attenuated live polioviruses (Sabin) to children with hypogammaglobulinemia. Presented at the 9th Symposium of the European Association of Poliomyelitis and Allied Diseases; 1963; Stockholm, Sweden.
6.
HaraMSaitoYKomatsuT, et al. Antigenic analysis of polioviruses isolated from a child with agammaglobulinemia and paralytic poliomyelitis after Sabin vaccine administration. Microbiol Immunol. 1981;25:905–13.
7.
NkowaneBMWassilakSGFOrensteinWA, et al. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA. 1987;267:1335–40.
8.
LiLIvanovaODrissN, et al. Poliovirus excretion among persons with primary immune deficiency disorders: summary of a seven-country study series. J Infect Dis. 2014;210(suppl 1):S368–72. DOI: 10.1093/infdis/jiu065
9.
ShaghaghiMShahmahmoodiSAbolhassaniH, et al. Vaccine-derived polioviruses and children with primary immunodeficiency, Iran, 1995-2014. Emerg Infect Dis. 2016;22:1712–9. DOI: 10.3201/eid2210.151071
10.
AghamohammadiAAbolhassaniHKutukculerN, et al. Patients with primary immunodeficiencies are a reservoir of poliovirus and a risk to polio eradication. Front Immunol. 2017;8:685. DOI: 10.3389/fimmu.2017.00685
11.
MohantyMCMadkaikarMRDesaiM, et al. Poliovirus excretion in children with primary immunodeficiency disorders, India. Emerg Infect Dis. 2017;23:1664–70. DOI: 10.3201/eid2310.170724
12.
ShaghaghiMShahmahmoodiSNiliA, et al. Vaccine-derived poliovirus infection among patients with primary immunodeficiency and effect of patient screening on disease outcomes, Iran. Emerg Infect Dis. 2019;25:2005–12. DOI: 10.3201/eid2511.190540
13.
MacklinGLiaoYTakaneM, et al. Prolonged excretion of poliovirus among individuals with primary immunodeficiency disorder: an analysis of the World Health Organization registry. Front Immunol. 2017;8:1103. DOI: 10.3389/fimmu.2017.01103
14.
MacklinGDiopOMHumayunA, et al. Update on immunodeficiency-associated vaccine-derived polioviruses - worldwide, July 2018-December 2019. MMWR Morb Mortal Wkly Rep. 2020;69:913–7. DOI: 10.15585/mmwr.mm6928a4
15.
World Health Organization. Polio vaccines: WHO position paper - March, 2016. Weekly Epidemiol Rec. 2016;91:145–68.
16.
KewOMSutterRWde GourvilleEMDowdleWRPallanschMA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59:587–635. DOI: 10.1146/annurev.micro.58.030603.123625
17.
KewOMMorris-GlasgowVLandaverdeM, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science. 2002;296:356–9.
18.
Duintjer TebbensRJPallanschMAKimJH, et al. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal. 2013;33:680–702. DOI: 10.1111/risa.12022
19.
Duintjer TebbensRJPallanschMAThompsonKM. Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs. BMC Infect Dis. 2015;15:379. DOI: 10.1186/s12879-015-1115-5
20.
KalkowskaDAPallanschMAThompsonKM. Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters. Epidemiol Infect. 2019;147:e295. DOI: 10.1017/S095026881900181X
21.
AlexanderJPJrEhresmannKSewardJ, et al. Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota. J Infect Dis. 2009;199:391–397.
22.
SniderCJBoualamLTallisG, et al. Concurrent outbreaks of circulating vaccine-derived poliovirus types 1 and 2 affecting the Republic of the Philippines and Malaysia, 2019-2021. Vaccine. 2023;41(suppl 1):A58–69. DOI: 10.1016/j.vaccine.2022.02.022
23.
WeilMRahavGSomechR, et al. First report of a persistent oropharyngeal infection of type 2 vaccine-derived poliovirus (iVDPV2) in a primary immune deficient (PID) patient after eradication of wild type 2 poliovirus. Int J Infect Dis. 2019;83:40–43. DOI: 10.1016/j.ijid.2019.03.037
MacklinGRPeakCEisenhawerM, et al. Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): novel oral polio vaccine type 2 (nOPV2) experience. Vaccine. 2023;41(suppl 1):A122–7. DOI: 10.1016/j.vaccine.2022.02.050
26.
Global Polio Eradication Initiative. GPEI Statement on cVDPV2 Detections in Burundi and Democratic Republic of the Congo. Geneva (Switzerland): World Health Organization, Global Polio Eradication Initiative; 2023.
27.
Konopka-AnstadtJLCampagnoliRVincentA, et al. Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. NPJ Vaccines. 2020;5:26. DOI: 10.1038/s41541-020-0176-7
28.
World Health Assembly. Poliomyelitis: mechanism for management of potential risks to eradication (resolution 61.1). Geneva (Switzerland): World Health Organization; May19–24, 2008. Available from: http://apps.who.int/gb/ebwha/pdf_files/WHA61-REC1/A61_Rec1-part2-en.pdf [Accessed 4 June, 2019].
29.
Duintjer TebbensRJPallanschMACochiSLWassilakSGThompsonKM. An economic analysis of poliovirus risk management policy options for 2013-2052. BMC Infect Dis. 2015;15:389. DOI: 10.1186/s12879-015-1112-8
30.
HamptonLMFarrellMRamirez-GonzalezA, et al. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine - worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2016;65:934–8. DOI: 10.15585/mmwr.mm6535a3
31.
KalkowskaDAPallanschMACochiSL, et al. Updated characterization of post-OPV cessation risks: lessons from 2019 serotype 2 outbreaks and implications for the probability of OPV restart. Risk Anal. 2021;41:320–8. DOI: 10.1111/risa.13555
32.
KalkowskaDAPallanschMAWilkinsonA, et al. Updated characterization of poliovirus outbreak response strategies for 2019-2029: impacts of the use of novel OPV2 strains. Risk Anal. 2021;41:329–48. DOI: 10.1111/risa.13622
33.
ThompsonKM. Polio eradication: what kind of world do we want?Lancet Infect Dis. 2022;22:161–3. DOI: 10.1016/s1473-3099(21)00458-8
34.
MacklinGRO’ReillyKMGrasslyNC, et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. Science. 2020;368:401–5. DOI: 10.1126/science.aba1238
World Health Organization. Meeting of the strategic advisory group of experts on immunization, April 2022: conclusions and recommendations. Wkly Epidemiol Rec. 2022;97:274–5.
37.
KalkowskaDAWassalikSGFWiesenE, et al. Coordinated global cessation of oral poliovirus vaccine use: options and potential consequences. Risk Anal. Epub ahead of print June21, 2023. DOI: 10.1111/risa.14158
38.
ThompsonKMKalkowskaDA. An updated economic analysis of the Global Polio Eradication Initiative. Risk Anal. 2021;41:393–406. DOI: 10.1111/risa.13665
39.
ThompsonKMKalkowskaDABadizadeganK. Polio health economics: assessing the benefits and costs of polio, non-polio, and integrated activities of the Global Polio Eradication Initiative. Gates Open Res. 2022;6:5. DOI: 10.12688/gatesopenres.13524.1
40.
ThompsonKMKalkowskaDA. Review of poliovirus modeling performed from 2000-2019 to support global polio eradication. Expert Rev Vaccines. 2020;19:661–86. DOI: 10.1080/14760584.2020.1791093
41.
KalkowskaDAThompsonKM. Health and economic outcomes associated with polio vaccine policy options: 2019-2029. Risk Anal. 2021;41:364–75. DOI: 10.1111/risa.13664
42.
ThompsonKMKalkowskaDABadizadeganK. No role for reintroducing OPV into the United States with respect to controlling COVID-19 [Response to the letter to the editor by Chumakov et al.]. Risk Anal. 2021;41:389–92. DOI: 10.1111/risa.13671
De PalmaAMPürstingerGWimmerE, et al. Potential use of antiviral agents in polio eradication. Emerg Infect Dis. 2008;14:545–51. DOI: 10.3201/eid1404.070439
45.
McKinlayMACollettMSHincksJM, et al. Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication. J Infect Dis. 2014;210:S447–53.
46.
CollettMSHincksJRBenschopK, et al. Antiviral activity of pocapavir in a randomized, blinded, placebo-controlled human oral poliovirus vaccine challenge model. J Infect Dis. 2017;215:335–43. DOI: 10.1093/infdis/jiw542
47.
Duintjer TebbensRJThompsonKM. Using integrated modeling to support the global eradication of vaccine-preventable diseases. System Dyn Rev. 2018;34:78–120. DOI: doi:10.1002/sdr.1589
48.
ThompsonKMKalkowskaDA. Potential future use, costs, and value of poliovirus vaccines. Risk Anal. 2021;41:349–63. DOI: 10.1111/risa.13557
49.
Duintjer TebbensRJPallanschMAKalkowskaDAWassilakSGCochiSLThompsonKM. Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal. 2013;33:703–49. DOI: 10.1111/risa.12044
50.
KalkowskaDAPallanschMAWassilakSGFCochiSLThompsonKM. Global transmission of live polioviruses: updated integrated dynamic modeling of the polio endgame. Risk Anal. 2021;41:248–65. DOI: 10.1111/risa.13447
ThompsonKMKalkowskaDABadizadeganK. Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation. Front Public Health. 2023;11:1098419. DOI: 10.3389/fpubh.2023.1098419
53.
ThompsonKMKalkowskaDABadizadeganK. Hypothetical emergence of poliovirus in 2020: part 2. Exploration of the potential role of vaccines in control and eradication. Expert Rev Vaccines. 2021;20:449–60. DOI: 10.1080/14760584.2021.1891889
54.
Duintjer TebbensRJPallanschMAKewOM, et al. Uncertainty and sensitivity analyses of a decision analytic model for posteradication polio risk management. Risk Anal. 2008;28:855–76. DOI: 10.1111/j.1539-6924.2008.01078.x
55.
Duintjer TebbensRJThompsonKM. Uncertainty and sensitivity analysis of cost assumptions for global long-term poliovirus risk managementJ Vaccines Vaccin. 2016;7:1000339. DOI: 10.4172/2157-7560.1000339
56.
ThompsonKMKalkowskaDA. Reflections on modeling poliovirus transmission and the polio eradication endgame. Risk Anal. 2021;41:229–47. DOI: 10.1111/risa.13484
57.
KalkowskaDAWiesenEWassalikSGF, et al. Worst-case scenarios: modeling uncontrolled type 2 polio transmission. Risk Anal. Epub ahead of print June21, 2023. DOI: 10.1111/risa.14159
58.
Duintjer TebbensRJHamptonLMWassilakSGFPallanschMACochiSLThompsonKM. Maintenance and intensification of bivalent oral poliovirus vaccine use prior to its coordinated global cessation. J Vaccines Vaccin. 2016;7:340. DOI: 10.4172/2157-7560.1000340
59.
KalkowskaDAThompsonKM. Expected implications of globally-coordinated cessation of serotype 3 oral poliovirus vaccine (OPV) before serotype 1 OPV. Risk Anal. 2021;41:312–9. DOI: 10.1111/risa.13590
60.
ThompsonKM. Polio endgame complexity: updating expectations for nOPV2. Lancet Infect Dis. Epub ahead of print May10, 2023. DOI: 10.1016/S1473-3099(23)00133-0
61.
KalkowskaDAPallanschMAWassilakSGFCochiSLThompsonKM. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response. Vaccine. 2023;41(suppl 1):A136–41. DOI: 10.1016/j.vaccine.2021.04.061
62.
AnasirMIZarifFPohCL. Antivirals blocking entry of enteroviruses and therapeutic potential. J Biomed Sci. 2021;28:10. DOI: 10.1186/s12929-021-00708-8
63.
BerminghamWHCanningBWiltonT, et al. Case report: clearance of longstanding, immune-deficiency-associated, vaccine-derived polio virus infection following remdesivir therapy for chronic SARS-CoV-2 infection. Front Immunol. 2023;14:1135834. DOI: 10.3389/fimmu.2023.1135834
64.
KalkowskaDABadizadeganKThompsonKM. Outbreak management strategies for cocirculation of multiple poliovirus types. Vaccine. 2023;41:3718–27. DOI: 10.1016/j.vaccine.2023.04.037
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
